Brief: Basilea Reports Progress On Implementation Of Its Strategy To Focus On Anti-Infectives

Basilea Pharmaceutica AG, Allschwil

27/06/2022 06:18

June 27 (Reuters) - BASILEA PHARMACEUTICA AG  BSLN.S :
    * REPORTS PROGRESS ON THE IMPLEMENTATION OF ITS STRATEGY TO
FOCUS
ON ANTI-INFECTIVES
    * ERADICATE PHASE 3 STUDY EXPLORING CEFTOBIPROLE FOR
TREATMENT OF
PATIENTS WITH STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) EXPECTED TO
REPORT RESULTS SHORTLY
    * SEPARATE TRANSACTIONS FOR TTK/PLK1 INHIBITOR (BAL0891) AND
PRECLINICAL ONCOLOGY PROJECTS EXPECTED TO BE CONCLUDED IN H2
2022
    * NO EXPANSION OF ONGOING LISAVANBULIN CLINICAL STUDIES;
EXPLORING
PARTNERING OPPORTUNITIES
    * DERAZANTINIB RIGHTS TO BE TRANSFERRED BACK TO MERCK & CO.
BY END
OF 2022
    * PARTNERING DISCUSSIONS FOR TTK/PLK1-INHIBITOR (BAL0891)
AND
PRECLINICAL ONCOLOGY ASSETS ARE WELL ADVANCED AND EXPECTED TO BE
CONCLUDED IN H2 2022
    * NO MATERIAL EXPENSES RELATED TO ONCOLOGY ACTIVITIES BEYOND
2022
AND SUSTAINABLE PROFITABILITY EXPECTED IN 2023
    * WITH REGARD TO FGFR INHIBITOR DERAZANTINIB, COMPANY HAS
DECIDED
TO TERMINATE LICENSE AGREEMENT AND RETURN RIGHTS TO MERCK & CO,
INC. BY END OF YEAR
    * STRATEGY IMPLEMENTATION ON TRACK

Source text for Eikon:  ID:nGNE8b70TP 
Further company coverage:  BSLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))